
How We Review Genetic Results
We review genetic data from consumer panels (23andMe, Ancestry) and clinical panels (Invitae, Color, Nucleus) by translating raw variants into pathway-based action: nutrient needs, drug metabolism, cardiovascular risk, and earlier screening timelines. The goal is precision strategy, not labels. Genetics loads the gun. Lifestyle pulls the trigger.
How Fishtown Medicine Reviews Genetic Results
Your genetics are the blueprint of your health, not your destiny. At Fishtown Medicine, we take your raw data from consumer companies like 23andMe or Ancestry, or from clinical panels like Invitae, Color, or Nucleus, and translate them into a high-leverage personalized care plan. We do not just look for "bad genes." We look for opportunities to optimize nutrition, medication choice, screening timelines, and lifestyle around your unique biology.What kind of genetic data can you send us?
You can send us several kinds of genetic data, and we can work with most of them:- Raw DNA data: If you have used 23andMe or Ancestry, you can download your raw .txt file and we run it through clinical-grade analysis tools.
- Clinical panels: Reports from companies like Invitae or Color used for cancer screening or familial hypercholesterolemia.
- Whole genome sequencing: A 30x WGS report from Nucleus or Nebula covers 100 percent of your DNA.
- Specialized panels: Pharmacogenomic tests, MTHFR-specific reports, APOE status, and BRCA testing.
What is our interpretation framework?
Our interpretation framework uses pathway analysis instead of single-gene labeling. We do not crown you "the MTHFR patient" or "the APOE4 patient." We ask: where does your biology need extra support?- Metabolic pathway: Genetic tendencies toward insulin resistance, high triglycerides, or fatty liver.
- Detoxification pathway: How well your body handles oxidative stress, alcohol, and environmental exposures.
- Cardiovascular pathway: Markers like Lp(a) and familial hypercholesterolemia variants that standard labs often miss.
- Longevity pathway: APOE status, polygenic risk scores for neurodegeneration, and protective strategies you can deploy today.
- Pharmacogenomics: How fast or slow you metabolize specific drug families (CYP2D6, CYP2C19, CYP3A4).
How does genetics change your care plan?
Genetics changes your care plan by replacing generalized advice with precision action. A few real examples:- Nutrient precision: A specific MTHFR variant may push us to use methylated B-vitamins instead of standard ones.
- Medication safety: CYP2D6 status changes the safe dose of antidepressants, opioids, and beta-blockers.
- Screening timelines: A high polygenic risk score for breast or colon cancer can move your preventive imaging timelines up by a decade.
- Cardiovascular targets: APOE4 carriers often need stricter ApoB and saturated-fat targets, since the gene amplifies risk from both.
- Hormone strategy: Variants in COMT and aromatase shape how we approach testosterone, estrogen, and progesterone optimization.
Guidance from the clinic
Actionable Steps for Genetic Agency
Equip your biology.- Download your raw data: Log into your consumer DNA account and download the raw data file today.
- Upload to Ultralight: Send the file as a secure attachment in the app.
- Schedule a deep-dive review: We typically need 7 to 10 days to process the data through our pathway models before a full consult.
- Pair with labs: Your genetic data is most useful when paired with current ApoB, fasting insulin, hsCRP, and hormone panels.
Key Takeaways
- Genetics is a blueprint, not a destiny.
- We translate raw data into actionable pathways.
- Genetic data informs nutrients, medications, and screening timelines.
- Privacy matters: your data lives in our HIPAA-compliant, encrypted system.
Scientific References
- Khera AV, et al. "Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations." Nature Genetics. 2018.
- Hou L, et al. "Pharmacogenomic Testing in Clinical Practice." American Journal of Health-System Pharmacy. 2020.
- Manchanda R, et al. "Cost-effectiveness of population-based BRCA1, BRCA2 mutation testing." JAMA Oncology. 2018.
- Genin E, et al. "APOE and Alzheimer disease: a major gene with semi-dominant inheritance." Molecular Psychiatry. 2011.
Dr. Ash is a board-certified internal medicine physician specializing in preventive medicine and healthspan optimization at Fishtown Medicine in Philadelphia.
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Still have a question?
He answers personally. Usually within a few hours.
Related Intelligence

Managing Labs and Imaging with Ease
Confused about where to go for labs or scans? Learn how Fishtown Medicine helps you navigate local Philadelphia diagnostics while maximizing your insurance coverage.

Boutique Scans & Whole-Body MRI: A Clinical Review
Is a full-body MRI worth it? Learn the pros and cons of boutique scans like Prenuvo and PET-CTs, and how Fishtown Medicine chooses the right cancer detection strategy.

Longevity Strategies | Fishtown Medicine
Strategies to extend your healthspan and optimize lifespan in Philadelphia.
Talk it through with Dr. Ash.
If anything you read here raised a question, this is a free 20-minute Warm Invitation Call. Pick a time and we’ll work through it together.
Loading scheduler...
Having trouble with the scheduler? Book directly on Dr. Ash’s calendar
